Science & Enterprise subscription

Follow us on Twitter

  • Research done at Massachusetts Institute of Technology in 2018 led to creation of 32 new start-up enterprises as w… https://t.co/XDS3u9zDEX
    about 16 hours ago
  • New post on Science and Enterprise: MIT Spins-Off 32 Start-Ups in 2018 https://t.co/MwJpYlGhwV #Science #Business #AAASmtg
    about 16 hours ago
  • New contributed post on Science and Enterprise: https://t.co/MCiZyaoc0I Ships Are Becoming Safer With Technology
    about 19 hours ago
  • A panel of data and behavioral scientists envision great potential for blockchain in science, but show few cases o… https://t.co/Ch0yJRek4W
    about 2 days ago
  • New post on Science and Enterprise: Blockchain and Science, Not Ready for Prime Time https://t.co/mYiRQ0j8vU #Science #Business #AAASmtg
    about 2 days ago

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn
INSTAGRAM

Drug Discovery Start-Up Gains $400M Financing

Glasses, computer screens

A 2 year-old company using computational techniques to find protein-targeting drugs raised $400 million in new financing, led by the venture funding arm of Softbank. . . . → Read More: Drug Discovery Start-Up Gains $400M Financing

Lilly, Biopharm Partner on Alzheimer’s Treatment in $2B Deal

Neurons illustration

Eli Lilly and Co. is licensing a a treatment candidate for Alzheimer’s disease from biopharmaceutical company AC Immune that aims to block accumulation of tau proteins in the brain. . . . → Read More: Lilly, Biopharm Partner on Alzheimer’s Treatment in $2B Deal

Nanotech Gene Therapy Company Raises $8.5M in Seed Funds

Editing DNA

A start-up company developing nanoscale particles to deliver gene-editing enzymes, including those for Crispr, is raising $8.5 million in its seed funding round. . . . → Read More: Nanotech Gene Therapy Company Raises $8.5M in Seed Funds

RNA Biotech Raises $604M in IPO

NASDAQ share price display

Moderna Therapeutics, a biotechnology enterprise developing therapies with synthetic RNA, issued its initial public stock offering, or IPO, on Thursday, raising more than $604 million. . . . → Read More: RNA Biotech Raises $604M in IPO

Janssen Licensing Cancer Antibodies in $1.8B Deal

Llama

An affiliate of drug maker Janssen Pharmaceutical is licensing a synthetic antibody to treat blood-related cancers from a developer of antibodies based on the immune system of llamas. . . . → Read More: Janssen Licensing Cancer Antibodies in $1.8B Deal

RNA Therapeutics Company Raises $30M in First Venture Round

Kevin Weeks

A company spun-off from a university biochemistry lab is raising $30 million to fund discovery of treatments targeting RNA, genetic material instructing protein production in cells. . . . → Read More: RNA Therapeutics Company Raises $30M in First Venture Round

Trial Underway for Inhaled Heart Rhythm Drug, Developer Raises $42M

Heartbeat graphic

A clinical trial is underway testing an inhaled therapy to quickly treat irregular heart rhythms, in cases where the problems occur occasionally and often resolve on their own. . . . → Read More: Trial Underway for Inhaled Heart Rhythm Drug, Developer Raises $42M

Synthetic DNA Company Raising $70 Million in IPO

NASDAQ share price display

A 5 year-old enterprise developing synthetic DNA for medical and agricultural chemicals, as well as data storage, is raising $70 million in its initial public stock offering. . . . → Read More: Synthetic DNA Company Raising $70 Million in IPO

Gene Silencing Technology Licensed in $3.7B Deal

RNA strand illustration

Dicerna Pharmaceuticals, developing treatments for disease that silence genes by interfering with their RNA instructions, is licensing its technology to drug maker Eli Lilly and Co . . . → Read More: Gene Silencing Technology Licensed in $3.7B Deal

Start-Up Developing Immunometabolism Therapies, Gains $30M Funding

T-cells illustration

A start-up enterprise founded by medical researchers in the U.S. and Europe is developing treatments for cancer and autoimmune disorders that change chemical reactions in immune system cells. . . . → Read More: Start-Up Developing Immunometabolism Therapies, Gains $30M Funding